FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213258431> ?p ?o ?g. }

• W4213258431 endingPage "235" @default.
• W4213258431 startingPage "221" @default.
• W4213258431 abstract "Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. To evaluate the effect of hepatic impairment on the pharmacokinetics of dacomitinib, two dedicated studies were conducted to inform optimal dosing.Study 1 (NCT01571388) evaluated the effect of mild and moderate hepatic impairment on the plasma pharmacokinetics, safety, and tolerability after a single oral dose of dacomitinib 30 mg, and Study 2 (NCT03865446) evaluated the same endpoints in a severe hepatic impairment population. Both studies were phase I, open-label, parallel-group studies. A one-way analysis of variance (ANOVA) with unequal variance assumption and hepatic impairment group as a fixed effect was used to compare the natural log of area under the plasma concentration-time curve extrapolated to infinite time (AUCinf), AUC from time zero to the last quantifiable concentration (AUClast), and maximum plasma concentration (Cmax) for each hepatic impairment group to the respective normal hepatic function group. Since dacomitinib is a cytochrome P450 (CYP) 2D6 substrate, only participants with extensive or intermediate CYP2D6 phenotypes were included in the primary analysis.The AUCinf for participants with mild, moderate, or severe hepatic impairment decreased by 6%, decreased by 23%, and increased by 4%, respectively, compared with normal hepatic function, while the Cmax for participants with mild, moderate, or severe hepatic impairment increased by 3%, decreased by 20%, and increased by 31%, respectively, compared with normal hepatic function. A single oral dose of dacomitinib 30 mg was well tolerated in all participants.Based on these pharmacokinetic results, dacomitinib pharmacokinetics of participants with mild, moderate, or severe hepatic impairment were not statistically different relative to participants with normal hepatic function based on the ANOVA analysis. No dacomitinib dose adjustments for patients with hepatic impairment are recommended.ClinicalTrials.gov NCT01571388, registered 5 April 2012; ClinicalTrials.gov NCT03865446, registered 6 March 2019." @default.
• W4213258431 created "2022-02-24" @default.
• W4213258431 creator A5000548110 @default.
• W4213258431 creator A5013237694 @default.
• W4213258431 creator A5022458239 @default.
• W4213258431 creator A5046819681 @default.
• W4213258431 creator A5060555090 @default.
• W4213258431 creator A5080856370 @default.
• W4213258431 date "2022-02-23" @default.
• W4213258431 modified "2023-09-25" @default.
• W4213258431 title "The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib" @default.
• W4213258431 cites W1963871015 @default.
• W4213258431 cites W1985289020 @default.
• W4213258431 cites W1994420004 @default.
• W4213258431 cites W2063280109 @default.
• W4213258431 cites W2066046379 @default.
• W4213258431 cites W2096198395 @default.
• W4213258431 cites W2097781997 @default.
• W4213258431 cites W2110841878 @default.
• W4213258431 cites W2125129553 @default.
• W4213258431 cites W2129360604 @default.
• W4213258431 cites W2129491055 @default.
• W4213258431 cites W2132157071 @default.
• W4213258431 cites W2135192471 @default.
• W4213258431 cites W2160982674 @default.
• W4213258431 cites W2166084034 @default.
• W4213258431 cites W2171139285 @default.
• W4213258431 cites W2471422459 @default.
• W4213258431 cites W2760639821 @default.
• W4213258431 cites W2770460146 @default.
• W4213258431 cites W2806325305 @default.
• W4213258431 cites W2920907492 @default.
• W4213258431 cites W2995595042 @default.
• W4213258431 cites W2996019668 @default.
• W4213258431 cites W3111257261 @default.
• W4213258431 cites W619396262 @default.
• W4213258431 cites W73001605 @default.
• W4213258431 doi "https://doi.org/10.1007/s40261-022-01125-x" @default.
• W4213258431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35195881" @default.
• W4213258431 hasPublicationYear "2022" @default.
• W4213258431 type Work @default.
• W4213258431 citedByCount "0" @default.
• W4213258431 crossrefType "journal-article" @default.
• W4213258431 hasAuthorship W4213258431A5000548110 @default.
• W4213258431 hasAuthorship W4213258431A5013237694 @default.
• W4213258431 hasAuthorship W4213258431A5022458239 @default.
• W4213258431 hasAuthorship W4213258431A5046819681 @default.
• W4213258431 hasAuthorship W4213258431A5060555090 @default.
• W4213258431 hasAuthorship W4213258431A5080856370 @default.
• W4213258431 hasBestOaLocation W42132584311 @default.
• W4213258431 hasConcept C112705442 @default.
• W4213258431 hasConcept C126322002 @default.
• W4213258431 hasConcept C143998085 @default.
• W4213258431 hasConcept C197934379 @default.
• W4213258431 hasConcept C22979827 @default.
• W4213258431 hasConcept C2777288759 @default.
• W4213258431 hasConcept C2778375690 @default.
• W4213258431 hasConcept C2908647359 @default.
• W4213258431 hasConcept C33664856 @default.
• W4213258431 hasConcept C526171541 @default.
• W4213258431 hasConcept C62231903 @default.
• W4213258431 hasConcept C71924100 @default.
• W4213258431 hasConcept C90924648 @default.
• W4213258431 hasConcept C98274493 @default.
• W4213258431 hasConcept C99454951 @default.
• W4213258431 hasConceptScore W4213258431C112705442 @default.
• W4213258431 hasConceptScore W4213258431C126322002 @default.
• W4213258431 hasConceptScore W4213258431C143998085 @default.
• W4213258431 hasConceptScore W4213258431C197934379 @default.
• W4213258431 hasConceptScore W4213258431C22979827 @default.
• W4213258431 hasConceptScore W4213258431C2777288759 @default.
• W4213258431 hasConceptScore W4213258431C2778375690 @default.
• W4213258431 hasConceptScore W4213258431C2908647359 @default.
• W4213258431 hasConceptScore W4213258431C33664856 @default.
• W4213258431 hasConceptScore W4213258431C526171541 @default.
• W4213258431 hasConceptScore W4213258431C62231903 @default.
• W4213258431 hasConceptScore W4213258431C71924100 @default.
• W4213258431 hasConceptScore W4213258431C90924648 @default.
• W4213258431 hasConceptScore W4213258431C98274493 @default.
• W4213258431 hasConceptScore W4213258431C99454951 @default.
• W4213258431 hasFunder F4320307765 @default.
• W4213258431 hasIssue "3" @default.
• W4213258431 hasLocation W42132584311 @default.
• W4213258431 hasLocation W42132584312 @default.
• W4213258431 hasLocation W42132584313 @default.
• W4213258431 hasOpenAccess W4213258431 @default.
• W4213258431 hasPrimaryLocation W42132584311 @default.
• W4213258431 hasRelatedWork W2037651778 @default.
• W4213258431 hasRelatedWork W2051764329 @default.
• W4213258431 hasRelatedWork W2064759457 @default.
• W4213258431 hasRelatedWork W2074207917 @default.
• W4213258431 hasRelatedWork W2094883508 @default.
• W4213258431 hasRelatedWork W2319060667 @default.
• W4213258431 hasRelatedWork W3087516196 @default.
• W4213258431 hasRelatedWork W3151787567 @default.
• W4213258431 hasRelatedWork W3178697376 @default.
• W4213258431 hasRelatedWork W4210689174 @default.
• W4213258431 hasVolume "42" @default.

• next